Research on the clinical value of tumor deactivation after radiofrequency ablation of liver cancer assessed by MDCT / 中国医学装备

ABSTRACT

Objective:To explore the clinical value of tumor deactivation after radiofrequency ablation of liver cancer assessed by MDCT.Methods: By CT perfusion combined with CT angiography and CT enhanced scan in 91 cases of liver cancer patients before and after radiofrequency ablation treatment, the change of tumor size, density change, scope of coagulation necrosis area and comparison sensitivity, specificity and accuracy of two methods diagnosis of recurrent or residual tumor were observed.Results:In the diagnosis of tumor recurrence or residual degree of sensitivity, specificity and accuracy CTP combine CTA were 100%, 95.3%, 96.2%, conventional enhanced CT were 33.3%, 88.4% and 78.8%. The diagnosis of recurrence or residual tumor after radiofrequency sensitivity and accuracy CTP combine CTA is higher than conventional enhancement CT, The difference was statistically significant(x2=6.912, x2=7.121;P<0.05). Both no statistical difference between specificity(x2=0.615,P<0.05).Conclusion: CTP combination CTA can accurately determine the tumor after radiofrequency ablation for inactivated and degree, and superior to the conventional enhanced CT, is an effective evaluation method of radiofrequency ablation with a high clinical value.